Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,121 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Inactivating mutations and hypermethylation of the NKX2-1/TTF-1 gene in non-terminal respiratory unit-type lung adenocarcinomas.
Matsubara D, Soda M, Yoshimoto T, Amano Y, Sakuma Y, Yamato A, Ueno T, Kojima S, Shibano T, Hosono Y, Kawazu M, Yamashita Y, Endo S, Hagiwara K, Fukayama M, Takahashi T, Mano H, Niki T. Matsubara D, et al. Among authors: hagiwara k. Cancer Sci. 2017 Sep;108(9):1888-1896. doi: 10.1111/cas.13313. Epub 2017 Jul 29. Cancer Sci. 2017. PMID: 28677170 Free PMC article.
Reliability of the peptide nucleic acid-locked nucleic acid polymerase chain reaction clamp-based test for epidermal growth factor receptor mutations integrated into the clinical practice for non-small cell lung cancers.
Tanaka T, Nagai Y, Miyazawa H, Koyama N, Matsuoka S, Sutani A, Huqun, Udagawa K, Murayama Y, Nagata M, Shimizu Y, Ikebuchi K, Kanazawa M, Kobayashi K, Hagiwara K. Tanaka T, et al. Among authors: hagiwara k. Cancer Sci. 2007 Feb;98(2):246-52. doi: 10.1111/j.1349-7006.2006.00377.x. Cancer Sci. 2007. PMID: 17233841 Free article.
Peptide nucleic acid-locked nucleic acid polymerase chain reaction clamp-based detection test for gefitinib-refractory T790M epidermal growth factor receptor mutation.
Miyazawa H, Tanaka T, Nagai Y, Matsuoka M; Huqun; Sutani A, Udagawa K, Zhang J, Hirama T, Murayama Y, Koyama N, Ikebuchi K, Nagata M, Kanazawa M, Nukiwa T, Takenoshita S, Kobayashi K, Hagiwara K. Miyazawa H, et al. Among authors: hagiwara k. Cancer Sci. 2008 Mar;99(3):595-600. doi: 10.1111/j.1349-7006.2007.00706.x. Cancer Sci. 2008. PMID: 18271876 Free article.
First-line gefitinib in patients aged 75 or older with advanced non-small cell lung cancer harboring epidermal growth factor receptor mutations: NEJ 003 study.
Maemondo M, Minegishi Y, Inoue A, Kobayashi K, Harada M, Okinaga S, Morikawa N, Oizumi S, Tanaka T, Isobe H, Kudoh S, Hagiwara K, Nukiwa T, Gemma A. Maemondo M, et al. Among authors: hagiwara k. J Thorac Oncol. 2012 Sep;7(9):1417-22. doi: 10.1097/JTO.0b013e318260de8b. J Thorac Oncol. 2012. PMID: 22895139 Free article. Clinical Trial.
A prospective PCR-based screening for the EML4-ALK oncogene in non-small cell lung cancer.
Soda M, Isobe K, Inoue A, Maemondo M, Oizumi S, Fujita Y, Gemma A, Yamashita Y, Ueno T, Takeuchi K, Choi YL, Miyazawa H, Tanaka T, Hagiwara K, Mano H; North-East Japan Study Group; ALK Lung Cancer Study Group. Soda M, et al. Among authors: hagiwara k. Clin Cancer Res. 2012 Oct 15;18(20):5682-9. doi: 10.1158/1078-0432.CCR-11-2947. Epub 2012 Aug 20. Clin Cancer Res. 2012. PMID: 22908099
Activity of EGFR-tyrosine kinase and ALK inhibitors for EML4-ALK-rearranged non-small-cell lung cancer harbored coexisting EGFR mutation.
Miyanaga A, Shimizu K, Noro R, Seike M, Kitamura K, Kosaihira S, Minegishi Y, Shukuya T, Yoshimura A, Kawamoto M, Tsuchiya S, Hagiwara K, Soda M, Takeuchi K, Yamamoto N, Mano H, Ishikawa Y, Gemma A. Miyanaga A, et al. Among authors: hagiwara k. BMC Cancer. 2013 May 29;13:262. doi: 10.1186/1471-2407-13-262. BMC Cancer. 2013. PMID: 23714228 Free PMC article.
1,121 results